Division of Nephrology, Department of Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Nephrol Dial Transplant. 2017 Feb 1;32(2):355-363. doi: 10.1093/ndt/gfw332.
Recent reports have suggested the possible benefit of beginning hemodialysis (HD) at a rate less frequent than three times weekly and incrementally increasing the dialysis dose. However, the data regarding the benefits and safety of incremental HD are insufficient.
We analyzed 927 patients with newly initiated HD from the Clinical Research Center for End-Stage Renal Disease cohort from 2008 to 2014. The patients were classified into a thrice-weekly initiation group or an incremental initiation group (one to two sessions per week) according to the frequency of HD per week at baseline. We compared health-related quality of life (HRQOL), daily urine volume at 12 months and all-cause mortality between the groups. We matched the thrice-weekly and incremental groups at a 1:2 ratio using propensity score matching.
A total of 312 patients (207 in the thrice-weekly group and 105 in the incremental group) were selected. All-cause mortality was comparable between the two groups before and after propensity score matching. The HRQOL tended to be better in the incremental group for the majority of domains of the Kidney Disease Quality of Life Short Form and Beck's Depression Inventory; however, only the symptoms and problems domain was significantly better in the incremental group at 3 months after HD. At 12 months after HD, there were no differences between the groups. The daily urine volume at 12 months after HD was similar between the two groups.
Incremental HD initiation showed comparable results to thrice-weekly initiation for HRQOL, residual renal function and all-cause mortality. Incremental HD may be considered an additional option for HD initiation in selected patients.
最近的报告表明,每周少于三次且逐渐增加透析剂量开始血液透析(HD)可能会带来益处。然而,关于增量 HD 的益处和安全性的数据还不够充分。
我们分析了 2008 年至 2014 年期间临床肾脏病研究中心终末期肾脏病队列中 927 名新开始 HD 的患者。根据基线时每周 HD 的频率,患者被分为每周三次起始组或递增起始组(每周一到两次)。我们比较了两组之间的健康相关生活质量(HRQOL)、12 个月时的每日尿量和全因死亡率。我们使用倾向评分匹配将每周三次和递增组按 1:2 的比例匹配。
共选择了 312 名患者(每周三次组 207 名,递增组 105 名)。在进行倾向评分匹配前后,两组之间的全因死亡率相当。在大多数肾脏病生活质量简表和贝克抑郁量表的领域,递增组的 HRQOL 往往更好;然而,只有在 HD 后 3 个月时,递增组的症状和问题领域才有显著改善。在 HD 后 12 个月时,两组之间没有差异。HD 后 12 个月时两组的每日尿量相似。
增量 HD 起始与每周三次起始相比,在 HRQOL、残余肾功能和全因死亡率方面结果相当。在选定的患者中,增量 HD 可能被认为是 HD 起始的另一种选择。